investiment.io
Kairos Pharma, Ltd.
$2.3
-0.16 (-6.5%)
Kairos Pharma, Ltd.
$2.3
-0.16 (-6.5%)
KAPA Price Chart
| Basic | |
|---|---|
| Market Cap | $29.54M |
| Price | $2.3 |
| 52 Week Range | 2.04-4.0 |
| Beta | 0 |
| Margins | |
| Gross Profit Margin | |
| Operating Profit Margin | |
| Net Profit Margin | |
| Valuation (TTM) | |
| P/E Ratio | |
| Price to Sales Ratio | |
| Price to Book Ratio | |
| PEG Ratio | |
Industry
Biotechnology
Sector
Healthcare
CEO
Dr. John S. Yu M.D., Ph.D.
Website
IPO Date
2024-09-16
Description
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
Phone
310-948-2356
Address
2355 Westwood Blvd., Los Angeles, CA, 90064, US